Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt)-Reference-Cited by-同舟云学术

Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt)

Published:2021-04-14 Issue:9 Volume:64 Page:5470-5484
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lugar Charles W.¹^ORCID,Clarke Christian A.¹,Morphy Richard¹,Rudyk Helene¹,Sapmaz Selma¹,Stites Ryan E.¹,Vaught Grant M.¹,Furness Kelly¹,Broughton Howard B.¹,Durst Greg L.¹,Clawson David K.¹,Stout Stephanie L.¹,Guo Sherry Y.¹,Durbin Jim D.¹,Stayrook Keith R.¹,Edmondson Denise D.¹,Kikly Kristy¹,New Nicole E.¹,Bina Holly A.¹,Chambers Mark G.¹,Shetler Pamela¹,Chang William Y.²,Chang Veavi Ching-Yun¹,Barr Rob¹,Gough Wendy H.¹,Steele Jimmy P.¹,Getman Brian¹,Patel Nita¹,Mathes Brian M.¹,Richardson Timothy I.¹

Affiliation:

1. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

2. Lilly Biotechnology Center, Eli Lilly and Company, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01918

Reference40 articles.

1. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases

2. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing